What did @the.hormone.doc actually say?
The core claim here is that menopause is "not a state of hormone deficiency" but rather "a state of lower stable levels." The creator also argued that women have more control over their menopause experience than they think, that solutions exist for severe symptoms, and pushed back on "anti-aging" framing in favor of "pro-aging" and healthy aging language. These are substantive positions, not throwaway Instagram positivity.
To be clear about what was and wasn't said: the creator did not claim menopause requires treatment, did not prescribe anything, and did not frame hormone therapy as a cure. The argument was philosophical and framing-based, centered on whether the post-menopausal state should be classified as a medical deficiency. That framing matters enormously for how women receive care and how they feel about their own bodies.
Does the science back this up?
Partly, but the "not a deficiency" framing is genuinely contested in endocrinology, and the creator deserves some scrutiny here rather than a free pass.
The "deficiency" debate has real stakes. The term matters clinically. Estrogen and progesterone decline dramatically at menopause, and those hormones have documented roles in bone density, cardiovascular function, thermoregulation, sleep architecture, and cognitive health. Saying lower levels are simply "stable" without acknowledging the downstream consequences glosses over real physiology. Manson et al. (2013, JAMA Internal Medicine) and the Women's Health Initiative follow-up work established that the timing of hormone therapy relative to menopause onset has significant effects on cardiovascular outcomes. That is not the biology of a neutral hormonal shift.
That said, the creator has a defensible point. Menopause is a universal, evolutionarily conserved biological event, not a pathology. The "grandmother hypothesis" literature (Hawkes, 2003, American Journal of Human Biology) suggests post-reproductive life has adaptive value. Framing it as deficiency can medicalize a normal transition and, as the creator implies, drive unnecessary anxiety.
What did they get wrong (or right)?
The "pro-aging" versus "anti-aging" argument is largely right, and it is good to hear it said plainly. Anti-aging language pathologizes normal biology, and the evidence that it harms women's self-perception is not trivial. The statement that women "probably got more adult life after menopause than before it" is demographically accurate for women in high-income countries. Life expectancy data from the ONS and CDC consistently show women in their late 40s and 50s have decades of expected life remaining.
Where the creator oversimplifies is the phrase "lower stable levels." Estrogen levels in perimenopause are anything but stable. Freeman et al. (2011, Menopause) documented profound hormonal volatility during the menopausal transition, with erratic estradiol fluctuations preceding the eventual stable low. Calling it simply "stable" could mislead women into thinking their symptoms during perimenopause are unusual or unrelated to hormone changes.
The reassurance that "there are solutions" for severe symptoms is appropriate and accurate, without being prescriptive. That balance is done well here.
What should you actually know?
The framing debate, deficiency versus natural transition, has real clinical consequences. Women who internalize menopause as a deficiency state may be more likely to pursue unnecessary or poorly timed interventions. Women who dismiss it as purely natural may delay getting help for genuinely debilitating symptoms. Both extremes cause harm.
The current consensus from the Menopause Society (formerly NAMS) and the British Menopause Society is that menopause hormone therapy is appropriate and beneficial for symptomatic women, particularly those under 60 or within 10 years of menopause onset. This is not framed as correcting a deficiency in those guidelines. It is framed as symptom management and risk reduction. That nuance matters.
For testosterone specifically, which is the category this video was filed under, the evidence base for women is narrower. The Global Consensus Position Statement on testosterone for women (Davis et al., 2019, Journal of Clinical Endocrinology and Metabolism) supports its use for hypoactive sexual desire disorder post-menopause but notes limited long-term safety data. The creator did not discuss testosterone in this clip, so that gap is worth flagging separately.
- Menopause is not classified as a disease by WHO, but its symptoms can be severe and warrant treatment.
- Hormone levels in perimenopause are volatile, not simply lower. The transition matters clinically.
- Anti-aging framing in menopause content has documented negative effects on how women perceive their health trajectory.
- Solutions for severe menopause symptoms exist and are evidence-backed, including hormone therapy when appropriately indicated.